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Abstract
Most clinical trials of non-small-cell lung cancer (NSCLC) exclude patients with poor 
ECOG performance status (PS). Thus, the efficacy of immune checkpoint inhibitors 
(ICIs) in patients with poor PS remains unclear. Herein, we used data from a retro-
spective cohort to assess the potential clinical benefits of ICIs in NSCLC patients 
with poor PS. Data from NSCLC patients who received ICI monotherapy at 9 institu-
tions between December 2015 and May 2018 were retrospectively analyzed. After 
excluding 4 patients who lacked PS data, a total of 527 ICI-treated patients, including 
79 patients with PS 2 or higher, were used for our analyses. The progression-free sur-
vival (PFS) and overall survival (OS) of patients with PS 2 or higher were significantly 
shorter compared with those of PS 0-1 patients (median PFS, 4.1 vs 2.0 months; 
P < .001 and median OS, 17.4 vs 4.0 months; P < .001). Among NSCLC patients 
with programmed cell death protein-ligand 1 (PD-L1) expression of 50% or higher 
who were treated with pembrolizumab as first-line therapy, the median PFS times 
of patients with PS 2 and 0-1 were 7.3 and 8.1 months, respectively. There was no 
significant difference in PFS between patients with PS 2 and 0-1 (P = .321). Although 
poor PS was significantly associated with worse outcomes in NSCLC patients treated 
with ICIs, pembrolizumab as a first-line treatment in NSCLC patients expressing high 
levels of PD-L1 could provide a clinical benefit, even in patients with PS 2.
K E Y W O R D S
immune checkpoint inhibitor, non-small cell-lung cancer, PD-L1, pembrolizumab, poor 
performance status
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1  | INTRODUC TION
Although non-small-cell lung cancer (NSCLC) remains a leading 
cause of cancer-related mortality, immunotherapy with immune 
checkpoint inhibitors (ICIs) has dramatically changed the landscape 
of NSCLC therapy. Treatment ICIs has been reported to provide 
long-term tumor control in 10%-15% of patients,1-3 in sharp contrast 
to treatments with cytotoxic chemotherapies or targeted molecular 
therapies.4,5
The ECOG scale performance status (PS) has been reported to 
be a prognostic factor in NSCLC.6-9 Often, NSCLC patients with PS 
2 or worse are excluded from most clinical trials, including studies 
involving the use of ICIs.1-3 Hence, even though the clinical useful-
ness of ICIs in NSCLC patients with PS 0 or 1 has been reported in 
numerous clinical trials, it remains unclear whether patients with 
PS 2 or worse can benefit from ICIs. The purpose of this study was 
to evaluate the clinical usefulness of ICIs in NSCLC patients with 
poor PS. To this end, we retrospectively analyzed data from 527 
NSCLC patients, including 79 patients with PS 2 or worse, who re-
ceived ICIs, and examined their clinical benefits in NSCLC patients 
with different PS.
2  | METHODS
2.1 | Patients
This is a branch study analyzing our data from the Okayama Lung 
Cancer Study Group-Immunotherapy Database (OLCSG-ID), which 
includes clinical data from NSCLC patients treated with ICIs for the 
purpose of various branch studies about ICI therapy in NSCLC.10 The 
OLCSG-ID includes the medical records of 531 NSCLC patients who 
received monotherapy with anti-programmed cell death protein-1 
(PD-1) or anti-programmed death-ligand 1 (PD-L1) Ab at 9 different 
institutions between December 2015 and May 2018. After exclud-
ing 4 patients who lacked PS data, we analyzed the data for the re-
maining 527 patients for this study.
2.2 | Statistical analyses
Differences between the different groups were analyzed using 
Fisher’s exact test. Progression-free survival (PFS) was defined 
as the time between the beginning of the ICI treatment to the 
day of disease progression or death from any cause. Overall sur-
vival (OS) was defined as the time between the beginning of ICI 
treatment to the day of death from any cause and was analyzed 
using the Kaplan-Meier method. Survival analysis was carried out 
using the log-rank test and multivariate Cox proportional haz-
ards model adjusted for confounding factors. Differences were 
deemed statistically significant if P was less than .05. All statisti-
cal analyses were carried out using STATA software (version 15.1; 
StataCorp).
3  | RESULTS
3.1 | Patient characteristics
Data from 527 patients were analyzed in this study. Patient char-
acteristics are shown in Table 1. There were 448 patients with PS 
0-1 (PS 0-1 group) and 79 patients with PS 2-4 (PS 2-4 group). The 
median age was 69 years (range, 28-96 years) in the PS 0-1 group and 
70 years (range, 37-87 years) in the PS 2-4 group. Mutations in the 
epidermal growth factor receptor (EGFR) gene were detected in 51 
patients (11.4%) in the PS 0-1 group and 8 patients (10.1%) in the PS 
2-4 group. Relative PD-L1 expression was 50% or higher in 113 pa-
tients (25.2%) in the PS 0-1 group and 22 patients (27.8%) in the PS 
2-4 group. The PD-L1 expression was undetermined in 220 patients 
(49.1%) in the PS 0-1 group and 42 patients (53.2%) in the PS 2-4 
group. In both groups, pembrolizumab and nivolumab were the most 
commonly used ICIs. The median body mass index (BMI) was 21.6 in 
the PS 0-1 group and 20.1 in the PS 2-4 group.
Except for PS, BMI was the only clinical factor that significantly 
differed between the groups.
3.2 | Performance status 2 or greater is associated 
with poor survival in NSCLC patients treated with ICIs
Patients with PS 0-1 had a significantly longer PFS than patients 
with PS 2-4 (median PFS, 4.1 vs 2.0 months, respectively, P < .001; 
Figure 1A). Univariate (hazard ratio [HR], 1.819; 95% confidence in-
terval [CI], 1.404-2.357) and multivariate analyses (HR, 1.908; 95% 
CI, 1.465-2.484) indicated that a PS of 2-4 was an independent fac-
tor predicting poor PFS (Table 2A).
Similarly, patients with a worse PS had a significantly shorter 
OS. The median OS in patients with a PS of 0-1 and 2-4 was 17.4 
and 4.0 months, respectively (Figure 1B). The OS was significantly 
shorter in patients in the PS 2-4 group than in the PS 0-1 group 
(P < .001). Univariate (HR, 3.526; 95% CI, 2.641-4.709) and multivar-
iate analyses (HR, 3.914; 95% CI, 2.908-5.269) revealed that a PS of 
2-4 was an independent factor predicting short OS (Table 2B).
To obtain further insight into the impact of PS on ICI therapy 
outcome, we stratified patients into 4 groups according to their PS 
(PS 0, 1, 2, and 3-4) and undertook survival analysis for each patient 
group (Figure 2). The median PFS times in patients in the PS 0, 1, 
2, and 3-4 groups were 6.9, 3.5, 2.3, and 1.1 months, respectively 
(Figure 2A). Furthermore, PFS was significantly shorter in patients 
with PS 1, 2, and 3-4 than patients with PS 0 (PS 1 vs PS 0: HR, 
1.336; 95% CI, 1.031-1.732; P = .026; PS 2 vs PS 0: HR, 1.451; 95% 
CI, 1.214-1.734; P < .001; PS 3-4 vs PS 0: HR, 2.410; 95% CI, 1.772-
3.277; P < .001). Similarly, OS was significantly shorter in patients 
with worse PS (Figure 2B). The median OS times in patients with PS 
0, 1, 2, and 3-4 were 20.4, 15.5, 5.0, and 1.9 months, respectively (PS 
1 vs PS 0: HR, 1.536; 95% CI, 1.092-2.160; P = .014; PS 2 vs PS 0: HR, 
2.088; 95% CI, 1.682-2.593; P < .001; PS 3-4 vs PS 0: HR, 4.619; 95% 
CI, 3.034-7.032, P < .001).
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3.3 | Characteristics of PS 2 patients who benefited 
from ICI therapy
Although patients with PS 2 or higher had worse survival after ICI 
therapy than those with PS less than 2, some patients with PS 2 
responded to ICI treatment, achieving disease control for more 
than 1 year. By contrast, all patients with PS 3-4 experienced 
disease progression or death in less than 10 months (Figure 2A). 
These observations suggest that certain patients with PS 2 could 
benefit from ICI therapy, despite their poor PS. Hence, we sought 
to assess the characteristics of patients with PS 2 who benefited 
from ICI therapy. Because the efficacies of pembrolizumab as a 
first-line treatment for NSCLC patients with PD-L1 expression of 
50% or higher and that of any ICIs as second- or later-line treat-
ments irrespective of PD-L1 expression in NSCLC patients are 
quite different, we stratified patients according to treatment strat-
egy and compared the outcomes of patients with PS 2 and PS 0-1 
(Figure S1). Cohort 1 included patients with NSCLC (PD-L1 expres-
sion 50% or higher) treated with pembrolizumab as first-line treat-
ment (Table S1), whereas cohort 2 included NSCLC patients with 
any PD-L1 expression who were treated with any ICI as second- or 
later-line therapy (Table S2).
Among patients with NSCLC with PD-L1 expression of 50% or 
higher who were treated with pembrolizumab as first-line therapy 
(cohort 1), the median PFS for patients with PS 2 was 7.3 months 
(95% CI, 1.5-11.4 months), whereas that of patients with PS 0-1 was 
8.1 months (95% CI, 4.8 months–not reached) (Figure 3A). There 
was no significant difference in PFS between patients with PS 2 
and PS 0-1 (P = .321). However, patients with PS 3-4 had a PFS of 
1.0 month (95% CI, 0.3 months-not reached) (Figure 3A), which was 
significantly worse than that of PS 0-1 patients (P < .001). Similar 
findings were observed for the OS (Figure 3B). The 1-year OS rates 
in patients with PS 2 and those with PS 0-1 were 53.0% (95% CI, 
20.9%–77.3%) and 69.7% (95% CI, 55.9%–79.9%), respectively. The 
PS 0-1 (n = 448) PS 2-4 (n = 79)
P 
value
PS (0/1/2/3/4) 103/345/0/0/0 (23/77/0/0/0) 0/0/64/13/2 (0/0/81/16/3) <.001
Median age, years 
(range)
69 (28-96) 70 (37-87)
Gender (male/
female)
352/96 (79/21) 64/15 (81/19) .765
Staging 
(recurrence/IIIB 
or IV)
131/317 (29/71) 18/61 (23/77) .279
Histology (Ad/Sq/
others)
286/129/33 (64/29/7) 51/20/8 (65/25/10) .563
Driver mutation 
(EGFR/ALK/WT 
or undetermined)
51/4/393 (11/1/88) 8/0/71 (10/0/90) .921
PD-L1 expression 
(0%-49%/50% or 
more/unknown)
115/113/220 (26/25/49) 15/22/42 (19/28/53) .462
Smoking status 
(never/ex 
or current/
unknown)
84/361/3 (18/81/1) 10/67/2 (13/84/3) .117
Treatment line 
(1st/2nd/3rd or 
more)
74/155/219 17/35/48) 17/30/32 (22/38/41) .325
Immune 
checkpoint 
inhibitors (Pem/
Nivo/Ate)
128/317/3 (29/70/1) 28/51/0 (35/65/0) .427
Median BMI 
(range)
21.6 (13.6-34.4) 20.1 (12.4-28.5) .001a
Abbreviations: Ad, adenocarcinoma; ALK, anaplastic lymphoma kinase; Ate, atezolizumab; BMI, 
body mass index; EGFR, epidermal growth factor receptor; Nivo, nivolumab; PD-L1, programmed 
cell death ligand 1; Pem, pembrolizumab; Sq, squamous cell carcinoma.
aData are shown as median (range) or n (%). 
at test. 
TA B L E  1   Characteristics of 527 
patients with non-small-cell lung cancer 
treated with immune checkpoint 
inhibitors, grouped according to ECOG 
performance status (PS)
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log-rank test revealed that there were no significant differences 
in these outcomes between the 2 groups (P = .148). In contrast, 
patients with PS 3-4 showed significantly worse OS than those 
with PS 0-1 (P < .001) (Figure 3B). These data suggest that there 
is a potential clinical benefit of pembrolizumab in NSCLC patients 
with PS 2 and PD-L1 of 50% or higher when used as a first-line 
treatment.
Among the patients in cohort 2, patients with PS 2 had a signifi-
cantly shorter PFS compared to patients with PS 0-1 (median PFS, 
2.0 vs 3.5 months, respectively; 95% CI, 1.6-2.8 vs 2.9-4.3 months; 
P < .001) (Figure 3C). The median OS and 1-year OS rates were 
4.7 months (95% CI, 3.0-8.2 months) and 26.0% (95% CI, 14.5-39.2%), 
respectively, in patients with PS 2, whereas patients with PS 0-1 
had median OS and 1-year OS rates of 16.7 months (95% CI, 14.9-
18.8 months) and 62.9% (95% CI, 57.4-67.9%), respectively. Patients 
with PS 2 had a significantly shorter OS than those with PS 0-1 
(P < .001). Patients with PS 3-4 had significantly shorter PFS and OS 
(median PFS, 1.1 months, P < .001; median OS, 1.7 months, P < .001; 
Figure 3C,D).
3.4 | Incidence of adverse effects is not higher in 
NSCLC patients with PS 2
Table 3 shows the adverse events (AEs) experienced by the 
NSCLC patients treated with ICIs. Adverse events of any grade 
were significantly less frequent in patients with PS 2 than in 
those with PS 0-1 (21.9% vs 34.8%, P = .047). Grade 3/4 AEs 
were observed in 37 patients (8.3%) in the PS 0-1 group and 9 
patients (14.1%) in the PS 2 group. This difference was not sta-
tistically significant (P = .157). Any grade and grade 3/4 AEs 
were observed in 26.7% and 6.7% of PS 3-4 patients, respec-
tively; the incidence of any grade and grade 3/4 AEs did not dif-
fer significantly between PS 3-4 and PS 0-1 patients (P = .593 
and P = 1.000, respectively).
4  | DISCUSSION
In the present study, we showed that, when given as a first-line 
treatment, pembrolizumab could provide a clinical benefit in NSCLC 
patients with PS 2 and PD-L1 expression of 50% or higher.
In this study, we found that PFS and OS were significantly 
shorter in NSCLC patients with worse PS. Previous retrospective 
studies investigating the efficacy of ICIs in patients with poor PS 
support our findings. Ahn et al reported a retrospective study of 
155 patients, including 34 patients with PS 2 or 3, and showed that 
patients with PS 2 or 3 who were treated with ICIs had significantly 
shorter OS than patients with PS 0-1.11 Ichiki et al12 also found 
that patients with PS 2 had significantly shorter OS than patients 
with PS 0-1 in a retrospective study of 44 ICI-treated patients, 6 of 
whom had a PS of 2. Fujimoto et al also showed that patients with 
PS 2 or higher had significantly shorter PFS than patients with PS 
0-1 in a retrospective study of 613 nivolumab-treated patients (in-
cluding 141 patients with PS 2 or higher).13 Across these studies, 
patients with poor PS consistently experienced poor outcomes 
after ICI therapy.
Patients with PS 3-4 had a significantly lower BMI in our study 
(Table 1). Several studies showed that low BMI was associated with 
poor outcomes in patients treated with ICIs.10 Preclinical studies 
have reported that adipose tissue secretes various proinflamma-
tory cytokines and chemokines, including leptin, tumor necrosis 
factor-alpha, and Interleukin-6.14-17 Additionally, obesity has been 
linked to PD-1-mediated T cell dysfunction and increased respon-
siveness to anti-PD-1/PD-L1 therapy.18 Poor outcomes after ICI 
therapy in patients with poor PS might be due to cachexia and 
lower fat content.
Despite the increasing evidence linking poor PS to worse ICI 
outcomes, no study has assessed the clinical benefit of first-line 
pembrolizumab treatment in NSCLC patients with poor PS and 
PD-L1 expression of 50% or higher. Therefore, it remained unclear 
whether patients with NSCLC with PD-L1 expression of 50% or 
F I G U R E  1   A, Progression-free survival (PFS) of patients with non-small-cell lung cancer treated with immune checkpoint inhibitors with 
performance status (PS) of 0-1 (solid line, n = 448) and 2-4 (dashed line, n = 79). B, Overall survival (OS) of patients with PS 0-1 (solid line, 
n = 448) and PS 2-4 (dashed line, n = 79). CI, confidence interval
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higher and poor PS should be treated with ICIs. Our study included 
NSCLC patients with PD-L1 of 50% or higher who were treated 
with pembrolizumab as a first-line treatment. Within this cohort, 
we found no significant differences in PFS or OS between patients 
with PS 2 and PS 0-1 (Figure 3A,B), implying that pembrolizumab 
has a potential clinical benefit even in patients with a PS of 2. 
Univariate analysis Multivariate analysis
HR 95% CI
P 
value HR 95% CI
P 
value
(A)
Gender
Female 1.350 1.071-1.701 .011 0.903 0.617-1.322 .601
Male 1.000 1.000
Staging
III or IV 1.470 1.175-1.840 .001 1.502 1.198-1.883 <.001
Recurrence 1.000 1.000
EGFR mutation
Positive 2.009 1.509-2.673 <.001 1.598 1.176-2.170 .003
WT or 
undetermined
1.000 1.000
Smoking
Ex or current 0.615 0.483-0.783 <.001 0.623 0.418-0.930 .021
Never 1.000 1.000
PS
2-4 1.819 1.404-2.357 <.001 1.908 1.465-2.484 <.001
0-1 1.000 1.000
Treatment line
2nd line or later 1.685 1.262-2.250 <.001 1.690 1.258-2.270 <.001
1st line 1.000 1.000
(B)
Gender
Female 1.050 0.786-1.403 .741 0.638 0.384-1.063 .084
Male 1.000 1.000
Staging
III or IV 1.377 1.046-1.813 .023 1.363 1.033-1.798 .029
Recurrence 1.000 1.000
EGFR mutation
Positive 1.356 0.958-1.918 .086 1.203 0.821-1.764 .344
WT or 
undetermined
1.000 1.000
Smoking
Ex or current 0.783 0.579-1.060 .113 0.554 0.324-0.949 .031
Never 1.000 1.000
PS
2-4 3.526 2.641-4.709 <.001 3.914 2.908-5.269 <.001
0-1 1.000 1.000
Treatment line
2nd line or later 1.463 0.999-2.141 .050 1.526 1.036-2.248 .033
1st line 1.000 1.000
Abbreviations: CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; 
PS, performance status.
TA B L E  2   Factors associated with (A) 
progression-free survival and (B) overall 
survival in patients with non-small-
cell lung cancer treated with immune 
checkpoint inhibitors
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F I G U R E  2   A, Progression-free survival (PFS) of patients with non-small-cell lung cancer treated with immune checkpoint inhibitors 
with performance status (PS) 0 (solid line, n = 103), PS 1 (dashed line, n = 345), PS 2 (dotted line, n = 64), or PS 3-4 (dashed and dotted line, 
n = 15). B, Overall survival (OS) of patients with PS 0 (solid line, n = 103), PS 1 (dashed line, n = 345), PS 2 (dotted line, n = 64), or PS 3-4 
(dashed and dotted line, n = 15). CI, confidence interval
F I G U R E  3   A, B, Progression-free survival (PFS) (A) and overall survival (OS) (B) of non-small cell lung cancer patients with programmed 
death-ligand 1 (PD-L1) expression ≥ 50% and performance status (PS) 0-1 (solid line, n = 68), PS 2 (dashed line, n = 11), or PS 3-4 (dotted 
line, n = 6), after first-line pembrolizumab treatment (cohort 1). C, D, PFS (C) and OS (D) of patients with PS 0-1 (solid line, n = 374), PS 2 
(dashed line, n = 53), or PS 3-4 (dotted line, n = 9) after treatment with any immune checkpoint inhibitor as second- or later-line therapy 
irrespective of PD-L1 expression (cohort 2). CI, confidence interval; NR, not reached
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Admittedly, the survival of patients with PS 0-1 seemed to be bet-
ter than that of patients with PS 2, although the difference was not 
statistically significant. The use of pembrolizumab as a first-line 
treatment for patients with PS 2 led to a markedly higher survival 
rate than chemotherapy, which has been reported to provide a 
median OS of 3-6 months and a 1-year OS rate of 10%-40%.19,20 
Even though the estimated median OS survival was not reached 
for these patients, the 1-year OS rate was higher than 50% in PD-
L1-high NSCLC patients with PS 2 who received pembrolizumab as 
a first-line treatment.
However, among patients treated with any ICI as a second- or 
later-line treatment, patients with PS 2 had significantly inferior 
PFS and OS compared with patients with PS 0-1. Within this co-
hort, the median PFS of patients with PS 2 was only 2.0 months, 
whereas the median OS was 4.7 months. These findings are similar 
to those of a retrospective study in which nivolumab was given to 
63 patients, including 20 patients with PS 2. That study reported 
a median PFS of 65 days and a median OS of 95 days for patients 
with PS 2.21 Therefore, the clinical significance of ICI therapy as a 
second- or later-line treatment for NSCLC patients with PS 2 remains 
controversial.
Importantly, NSCLC patients with PS 2 did not show a higher 
incidence of AEs of any grade after treatment with ICIs (Table 3). 
Nevertheless, it should be noted that the duration of treatment was 
shorter in patients with PS 2 than in those with PS 0-1 (Figure 2A), 
which could partly explain the lower frequency of AEs in patients 
with PS2. Therefore, these results need to be interpreted cautiously.
There are some limitations to this study. First, this study was 
retrospective; thus, the patient data were heterogeneous, and the 
results should be interpreted with caution. Second, to confirm the 
efficacy of ICIs in patients with poor PS, comparative analyses be-
tween patients with and without ICI treatment are necessary; how-
ever, our study lacked data from patients who did not receive ICIs. 
Finally, the combination of ICIs and chemotherapy is currently the 
first-line treatment for NSCLC22,23; nevertheless, our analyses did 
not include patients treated with combination therapy as the data 
used were obtained prior to the approval of the combination ther-
apy. Therefore, whether the combination of ICI and chemotherapy is 
safe and effective for patients with PS 2 remains unclear. Given that 
chemotherapy outcomes are inferior in patients with PS 2 than in 
those with better PS, the use of ICI and chemotherapy as a combina-
tion therapy should be undertaken with care.
In conclusion, we undertook a retrospective analysis of 527 
NSCLC patients who were treated with ICIs. Although poor PS was 
significantly associated with worse outcomes in these patients, pem-
brolizumab could be considered as a first-line treatment option for 
PD-L1-high NSCLC patients.
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